12:00 AM
 | 
Aug 29, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Simponi golimumab regulatory update

The U.K.'s NICE issued final guidance recommending the use of Simponi golimumab from Johnson & Johnson and Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) to treat ankylosing spondylitis in patients who have active spinal disease and have failed treatments with >=2 NSAIDs. The recommendation is contingent on a patient access scheme in which...

Read the full 260 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >